Hubei Biocause Pharmaceutical Co., Ltd. (000627) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hubei Biocause Pharmaceutical Co., Ltd.

Why is Hubei Biocause Pharmaceutical Co., Ltd. ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of -2.94% and Operating profit at -174.64%

Negative results in Sep 24

NET PROFIT(9M) At CNY -333.1 MM has Grown at -56.39%
OPERATING CASH FLOW(Y) Lowest at CNY -18,358.27 MM
DEBT-EQUITY RATIO (HY) Highest at 42.31 %

Risky - Not traded in last 10 days

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 0%, its profits have fallen by -710.6%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hubei Biocause Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Hubei Biocause Pharmaceutical Co., Ltd.

-33.61%

0.20

76.61%

China Shanghai Composite

15.19%

0.56

20.54%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-2.94%

EBIT Growth (5y)

-174.64%

EBIT to Interest (avg)

44.73

Debt to EBITDA (avg)

175.86

Net Debt to Equity (avg)

0.80

Sales to Capital Employed (avg)

1.10

Tax Ratio

11.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.03%

ROE (avg)

3.29%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.62

EV to EBIT

EV to EBITDA

481.11

EV to Capital Employed

0.71

EV to Sales

0.48

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

-6.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Hubei Biocause Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 128.15 MM has Grown at 124.55%

over average net sales of the previous four periods of CNY -521.97 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 31.92 MM has Grown at 115.39%

over average net sales of the previous four periods of CNY -207.35 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Profit

Highest at CNY 140.99 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin

Highest at 3.24 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY 128.15 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 31.92 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.01

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hubei Biocause Pharmaceutical Co., Ltd.

Net Sales

At CNY 4,354.27 MM has Fallen at -61.42%

over average net sales of the previous four periods of CNY 11,287.61 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY -18,358.27 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Lowest at CNY 4,354.27 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Debt-Equity Ratio

Highest at 42.31 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio